Navigation Links
SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Date:8/7/2008

cs. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing. The results of early preclinical studies or clinical trials may not be predictive of future results, and the Company cannot provide any assurances that any of its compounds or development candidates will have favorable results in preclinical studies or future clinical trials. In addition, results may be affected by the failure to enter into new collaborations on any of its research and development programs in the event that the merger transaction is not consummated, competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, the scope and validity of patent protection for its products, and its ability to obtain additional funding to support its operations. For a discussion of these and other factors, please refer to the risk factors described in the Company's annual report on Form 10-K for the year ended December 31, 2007 and the Company's most recent quarterly report on Form 10-Q as well as subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and SGX undertakes no obligation to revise or update this press release to reflect events or circumstances af
'/>"/>
SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
9. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
10. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
11. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Oct 24, 2014 Research and Markets ... Market by Product , Research Area & by End ... their offering. In this report, the ... products, research areas, and end users. The product segments ... enzymes, instruments & consumables, kits, and reagents. The subsegments ...
(Date:10/22/2014)... October 21, 2014 The Americas ... inorganic refrigerants market in Americas with analysis and ... of the Americas Inorganic Refrigerants Market report, to ... This also provides a glimpse of the segmentation ... supported by various tables and figures. , ...
(Date:10/22/2014)... Diego, CA (PRWEB) October 22, 2014 ... balances from Sartorius, A & D Weighing, Rice ... Sartorius CPA Semi-Micro Balance . The Sartorius CPA ... for an affordable high-quality, precise, and user-friendly laboratory ... manufacturing of laboratory equipment, their laboratory balances are ...
(Date:10/22/2014)... Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or ... next steps for its Oral Amphotericin B program.  ... in vitro work involving samples from ... plans to complete pre clinical studies and regulatory ... 1A clinical trial, utilizing approximately $700,000 of funding ...
Breaking Biology Technology:Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3
... July 10 CV Therapeutics,Inc. (Nasdaq: CVTX ) ... European Medicines Agency (EMEA) for ranolazine for,the treatment of ... (EU),member states. This approval follows a positive opinion from ... on April 24, 2008., Ranolazine is approved for ...
... MADISON, N.J., July 10 Quest Diagnostics,Incorporated (NYSE: ... and services, announced today that its second-quarter,2008 results will ... market,opens, and that it will hold its quarterly conference ... a.m. ET on that day., The public may ...
... Inc. (Nasdaq: ALXN ), today announced that the ... on Tuesday, July 29, 2008, at,10:00 a.m. Eastern Time ... for the second quarter ended June 30, 2008. Alexion,anticipates ... Tuesday,July 29, 2008., To participate in this conference ...
Cached Biology Technology:CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina 2CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina 3Quest Diagnostics to Release Second Quarter 2008 Financial Results 2
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
(Date:10/16/2014)... Calif. (October 16, 2014) – Post-menopausal women experienced ... on hormone levels or genital bleeding, after 12 ... an investigational fermented soy germ-based nutritional supplement previously ... to a new peer-reviewed pilot study reported in ... (NAMS) annual scientific meeting. , "These data ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... Grand Canyon may be so old that dinosaurs once lumbered ... the University of Colorado at Boulder and the California Institute ... radiometric dating to show the Grand Canyon may have formed ... origins by 40 million to 50 million years. The ...
... researchers is needed to make progress towards one ... marks contribute to regulation of gene expression. This ... European Science Foundation (ESF), Computational Approaches to the ... Epigenetics studies features of the DNA and chromatin ...
... NEW YORK, April 9 e-Smart(R) Technologies,Inc. ... and its parent,company, IVI Smart Technologies, Inc., ... filed in a Motion last month by,IDsmart ... Northern District of,California, San Francisco Division, Case ...
Cached Biology News:Grand Canyon may be as old as dinosaurs, says new study 2Grand Canyon may be as old as dinosaurs, says new study 3Computation to unravel how genes are regulated and shed light on how cells become different 2Computation to unravel how genes are regulated and shed light on how cells become different 3IDsmart Admits in Court Document That e-Smart's Technology was Used to Develop IDsmart's Smart Card 2IDsmart Admits in Court Document That e-Smart's Technology was Used to Develop IDsmart's Smart Card 3
Ephrin A4...
Rad51B...
... Rabbit polyclonal to Ki67 - Proliferation Marker, ... cell cycle related nuclear protein, expressed by ... active cell cycle (G1, S, G2 and ... (G0) cells. Ki67 antibodies are useful in ...
... reactive against the complex IV assembly factor SURF1. ... cultured cells. SURF1 is an important assembly factor ... participate in the folding of subunit II and ... SURF1, particularly ones that result in an absence ...
Biology Products: